We just recently published what we call a “population effectiveness model” in Value in Health, entitled “Estimated Life Years Saved in Women with HER2 Positive Metastatic Breast Cancer Receiving First-Line Trastuzumab and Pertuzumab In the United States”. We estimated the life years saved due to metastatic HER2 positive breast cancer after the introduction of trastuzumab, and we project the additional life years that could be saved after the introduction of pertuzumab. It is available via a free download until December 12, 2015 at the following link.

A population effectiveness model is one that take a population view of an intervention and assesses its effectiveness in the “real world” (i.e., the population). We have done quite a few of these kinds of models, which will be the subject of a future blog post. But for now, click on the link above and take a look.